ATHE logo

Alterity Therapeutics Limited

ATHE
Healthcare|Biotechnology|AU
$2.43
+0.21 (+9.46%)
DCF Value
$1.70
Tangible Book / Share
$117.86
Cash / Share
$102.94

Ownership Breakdown

68.5%
Float
16.9M
Shares Outstanding
11.6M
Float Shares

Insider Trades (21)

Last 4 quarters: 0 acquired · 0 disposed
InsiderPositionDateTypeSharesPriceValueFiling
Marks Peter AshleydirectorAug 31, 2026BUY47,620$0.50$23.8KForm 4
Marks Peter AshleydirectorAug 31, 2026BUY47,620$0.50$23.8KForm 4
Stamler David Allendirector, officer: Chief Executive OfficerAug 31, 2026BUY47,620$0.50$23.8KForm 4
Babarczy Julian MichaeldirectorJun 15, 2026AWARD2,000,000$1.00$2.0MForm 4
Gozlan Lawrence BernarddirectorJun 15, 2026AWARD1,000,000$1.00$1.0MForm 4
Cunningham Ann Michelledirector: Apr 17, 2026OTHER0——Form 4
Stamler David Allendirector, officer: Chief Executive OfficerApr 15, 2026OTHER0——Form 4
Stamler David Allendirector, officer: Chief Executive OfficerApr 15, 2026OTHER0——Form 4
Stamler David Allendirector, officer: Chief Executive OfficerApr 15, 2026OTHER40,000,200$0.00$120.0KForm 4
Stamler David Allendirector, officer: Chief Executive OfficerApr 15, 2026OTHER1,515,152$0.03$42.4KForm 4
Stamler David Allendirector, officer: Chief Executive OfficerApr 15, 2026OTHER2,380,952$0.01$23.8KForm 4
Stamler David Allendirector, officer: Chief Executive OfficerApr 15, 2026OTHER290,400,000$0.01$2.5MForm 4
Gozlan Lawrence BernarddirectorApr 10, 2026OTHER0——Form 4
Gozlan Lawrence BernarddirectorApr 10, 2026OTHER1,515,152$0.03$42.4KForm 4
Gozlan Lawrence BernarddirectorApr 10, 2026OTHER50,000,000$0.01$500.0KForm 4
Babarczy Julian Michaeldirector: Apr 10, 2026OTHER0——Form 4
Marks Peter AshleydirectorApr 10, 2026OTHER0——Form 4
Marks Peter AshleydirectorApr 10, 2026OTHER606,061$0.03$17.0KForm 4
Marks Peter AshleydirectorApr 10, 2026OTHER30,000,000$0.01$300.0KForm 4
Macnish Niven Abby SarahChief Financial OfficerApr 9, 2026OTHER0——Form 4
Macnish Niven Abby SarahChief Financial OfficerApr 10, 2026OTHER151,510$0.03$4.2KForm 4